The Alzheimer’s Association and partners have launched the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET). Learn more and get involved as an affiliated site or study: https://alz.org/alznetwork.
In a conversation with principal investigators and stakeholders, learn about the phases of building and implementing ALZ-NET, a national network to collect data on new FDA-approved Alzheimer’s drugs and therapies.
This webinar includes details about:
• How data will be collected and processed so that it is regulatory grade, yet flexible and customizable for different studies.
• How ALZ-NET will support clinical readiness to implement new treatments through training and education.
• Why now is a crucial moment to build ALZ-NET infrastructure: We are at the beginning of a new phase where multiple novel FDA-approved treatments may become available. To provide access to new treatments and improve care, there must be a therapeutic-agnostic network that collects real-world data and evidence.
Watch the one-hour webinar to learn more about progress so far, frequently asked questions, and how to become a site or affiliated study as part of ALZ-NET.
MORE FROM THE ALZHEIMER’S ASSOCIATION
ALZ-NET: https://alz.org/alznetwork
New IDEAS Study: https://alz.org/newideas
More on Alzheimer’s research: https://alz.org/research
Resources for researchers, clinicians and other professionals: https://www.alz.org/professionals
